Form 4: Lineage Cell Therapeutics CFO Jill Ann Howe Reports Acquisition of 10,500 Common Shares

Jill Ann Howe, CFO of Lineage Cell Therapeutics, reports acquiring 10,500 common shares at $0.89 per share on August 16, 2024.

Summary

• On August 16, 2024, Jill Ann Howe, the Chief Financial Officer of Lineage Cell Therapeutics, acquired 10,500 common shares of the company.
• The shares were purchased at a price of $0.89 per share.
• Following the transaction, Ms. Howe directly owns 10,500 common shares of Lineage Cell Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO in this case, trade their company's stock. These filings are closely watched by investors for insights into management's confidence in the company's prospects.

Stakeholder Impact

• The purchase of shares by a company insider can sometimes boost investor confidence.

Key Dates